Morphologic distinction of Mu¨llerian carcinomas from non-Mu¨ller-ian carcinomas in effusion specimens by cytomorphology alone can be diagnostically challenging. Therefore, immunohistochemical adjuncts can be useful in differentiating Mu¨llerian from non-Mu¨l-lerian metastases. In this study, we evaluated the expression of PAX8 and PAX2 in malignant effusions collected from patients with known Mu¨llerian and non-Mu¨llerian carcinomas. Sections from cell blocks prepared from 152 effusion specimens (54 and 98 cases representing metastases from Mu¨llerian and non-Mu¨llerian primaries, respectively) were immunostained with rabbit polyclonal antibodies against PAX8 and PAX2. Immunopositivity was defined as the presence of strong nuclear staining in at least 25% of the tumor cells. Fifty-two (96%) and 13 (24%) of the 54 Mu¨l-lerian carcinomas were positive for PAX8 and PAX2, respectively. PAX8 positivity was seen in only four (4%) of 98 non-Mu¨llerian carcinomas; these represented metastasis from a large cell neuroendocrine lung carcinoma, papillary thyroid carcinoma, renal cell carcinoma, and acinic cell carcinoma of the parotid gland. PAX2 positivity was not seen in any of the non-Mu¨llerian carcinomas. The results demonstrate that both PAX8 and PAX2 are highly specific markers for metastatic Mu¨llerian carcinomas in cell block preparations from effusion specimens (96% and 100%, respectively). PAX8, however, is more sensitive than PAX2 in identifying Mu¨llerian carcinomas in fluids (96% versus 24%). Overall, immunohistochemistry for PAX8 and PAX2 represent diagnostically useful adjuncts in identifying a Mu¨llerian carcinoma as a source of a malignant effusion. Diagn. Cytopathol. 2011;39:651-656. '
Metastatic carcinoma represents a common cause of fluid accumulation in the pleural, peritoneal, and pericardial spaces. In some cases, there is a known cancer history at the time a malignant effusion is diagnosed. Nonetheless, in other cases, a malignant effusion is diagnosed in the absence of a known primary malignancy. 1 Occasionally, cytologic evaluation of an effusion specimen can uncover the presence of a distinct primary in the setting of a previously documented cancer history. It is therefore important to determine or confirm a metastasis from a particular primary site as this will yield clinically useful information about the nature and extent of disease and facilitate the tailoring of optimal treatment regimens. 2 Because of overlapping cytomorphologic features of carcinomatous effusions by various primaries, 3 confident identification of a primary can be difficult by cytomorphologic evaluation alone. Therefore, immunohistochemistry is often employed to gain insight into the primary site. [4] [5] [6] Malignancies of the female gynecological (Müllerian) tract often present initially as ascites and effusions. The accurate diagnosis of malignant effusions resulting from metastatic Müllerian carcinomas is essential as specific chemotherapeutic regimens are used to treat distinct Mül-lerian carcinomas. For instance, high-grade serous carcinomas are typically treated with combination chemotherapy consisting of carboplatin and paclitaxel. 7 Furthermore, because these cancers usually present at an advanced stage, neoadjuvant chemotherapy with subsequent debulking surgery can be considered as a treatment option in cases where the extent of disease is deemed unresectable at initial presentation. 8 Also, the development of an effusion can indicate recurrence of malignancy after treatment. In both contexts, cytologic evaluation of effusions represents a minimally invasive method to obtain a specific pathologic diagnosis; accurately diagnosing a metastasis from a Müllerian carcinoma in effusions can lead to appropriate, prompt treatment.
The most common Müllerian carcinoma to present in effusions is serous carcinoma which is known to originate in the ovary, fallopian tube, peritoneum, and endometrium, 9 the majority of which are high-grade and manifest as single cells or small clusters in fluids. This cytomorphologic presentation can overlap with carcinomas originating from other primary sites such as breast, lung, and pancreas. 3, 10 Furthermore, in some cases, individual tumor cells can be difficult to distinguish from reactive mesothelial cells. Thus, especially in cases where the primary site of malignancy is unknown, diagnosing a malignant effusion and subsequently distinguishing a Müllerian from a non-Müllerian malignancy with certainty by cytomorphology alone can be challenging.
Immunohistochemical adjuncts have been previously reported in the diagnosis of Müllerian carcinomas. Notably, high-grade serous carcinomas are often immunoreactive for p53 11 and WT-1. 12, 13 However, mesothelial cells are also immunoreactive for WT-1 and reactive mesothelium can occasionally be p53-positive 14 thereby rendering immunohistochemical stains for WT-1 and p53 difficult to interpret in some cases. Furthermore, immunoreactivity for ER and PR can support Müllerian origin; however, positivity for these hormone receptors can often be seen in the context of malignant effusions secondary to metastatic breast carcinomas. 15 Recently the transcription factors, PAX2 and PAX8, have been reported to be expressed in Müllerian-derived epithelium such as the fallopian tube epithelium. [16] [17] [18] Furthermore, studies have shown that their expression is maintained in malignant tumors derived from this epithelium. For instance, Roh et al. have reported strong, diffuse PAX8 expression in the vast majority of serous carcinomas. 19 Furthermore, Tong et al. also reported that PAX2 is positive in a significant proportion of Müllerian carcinomas. 18 In addition, Nonaka et al. and Chivukula et al. investigated the utility of PAX8 and PAX2, respectively, to differentiate ovarian carcinomas from breast carcinomas in surgically resected specimens. 20, 21 To date, there are no reports that investigate the utility of PAX2 and PAX8 immunohistochemistry in effusion specimens. Therefore, we sought to investigate the diagnostic utility of immunohistochemistry for PAX2 and PAX8 as adjuncts to cytology in the identification and differentiation of Müllerian carcinomas from non-Müller-ian carcinomas in effusions.
Methods
After approval was obtained from the Institutional Review Board at University of Michigan, the electronic pathology database along with surgical pathology reports, clinical notes, and radiology reports were examined to identify patients in whom carcinomatous effusions (pleural, peritoneal, and pericardial) from a known primary site were diagnosed from 2000 to 2003. The slides prepared from each effusion specimen were reviewed and cases in which sufficient tumor was present in the formalin-fixed, paraffin-embedded cell block preparations were identified by examining recut, Hematoxylin and Eosin (H&E) stained slides. A total of 152 malignant effusions, one from each patient, were included in this study (Table I) .
Immunohistochemistry was performed using the DAKO Autostainer (DAKO, Carpinteria, CA) using DAKO LSAB+ and 3,3 0 -diaminobenzidine as the chromogen. For each case, 4-lm unstained sections were prepared from the cell blocks, deparaffinized, and immunostained after antigen retrieval in 0.01M citrate buffer, pH 6.0 (DAKO, Carpinteria, CA). Immunohistochemistry was performed using the rabbit polyclonal anti-PAX2 (1:100 dilution; Invitrogen, Camarillo, CA) and rabbit polyclonal anti-PAX8 (1:200 dilution; Protein Tech, Chicago, IL) antibodies along with appropriate controls. The EnVision+ System for use with rabbit primary antibodies (DAKO, 
Results
A total of 152 patients with metastatic carcinomatous effusions from a known primary site were identified and represented the source of material utilized in this study (Table I) . Fifty-four (36%) patients were diagnosed with a malignant effusion secondary to a Müllerian primary malignancy (ovary, fallopian tube, primary peritoneal, and endometrium); the majority of these (44 of 54; 81%) represented high-grade serous carcinomas. Table I . Immunohistochemistry revealed strong nuclear immunoreactivity for PAX8 in at least 25% of the tumor cells in 56 cases. Specifically, over 50% of the tumor cells were positive in 52 cases and between 25% and 50% of the tumor cells were positive in the remaining four. Fifty-two of the PAX8(+) malignant effusions represented metastases from Müllerian primaries (Table II) , which included serous carcinomas, carcinosarcomas, clear cell carcinomas, and the one case of endometrioid carcinoma (Fig. 1) . In one additional case of serous carcinoma, only rare tumor cells (*1% of the total tumor cell population) were highlighted by the PAX8 immunostain; this case was scored as negative, however, as the vast majority of the tumor cells were negative for PAX8. Of note, in each of the carcinosarcoma cases, the sarcomatous component was not present in the malignant effusion. Overall, the sensitivity for PAX8 in detecting Müllerian malignancies in fluids was 96% (52/54). The four remaining PAX8(+) cases represented malignant effusions secondary to non-Mullerian primaries including: a large cell neuroendocrine carcinoma of the lung; papillary thyroid carcinoma; and an acinic cell carcinoma of the parotid gland; and a renal cell carcinoma, clear cell type (Fig. 2) . In the remaining nonMullerian carcinomas examined, none of the tumor cells were positive for PAX8. Overall, four of the 98 non-Müller-ian malignant effusions were positive for PAX8; thus, the specificity of PAX8 for identifying Müllerian malignancies was 96% (Table II) .
Next, immunohistochemistry for PAX2 revealed strong nuclear PAX2 immunoreactivity in 13 cases (Table I ). All 13 cases were malignant effusions secondary to Müllerian primaries (Table II) . In eight cases, over half of the tumor cells were highlighted by PAX2 and 25-50% of the tumor cells were PAX2(+) in the remaining five. The remainder of the Müllerian carcinomas and all of the non-Müllerian carcinomas were completely negative for PAX2. Overall, the sensitivity for PAX2 in detecting Müllerian malignancies in effusions was 24% (13/54). Because none of the non-Müllerian tumors were PAX2(+), the specificity of PAX2 for identifying Müllerian malignancies in fluids was 100%. Of note, all 13 PAX2(+) tumors were also PAX8(+). Finally, in every case, PAX8 and PAX2 immunohistochemistry failed to highlight the background mesothelial cells and histiocytes in this study (Fig. 1) .
Discussion
Recently, the expression of the transcription factors, PAX2 and PAX8, have been reported in carcinomas of the female genital tract including serous, endometrioid, and clear cell carcinomas. 18, 20, 21 As there are no studies to date that have investigated the application of PAX2 and PAX8 immunohistochemistry to effusions, we sought to determine the expression of these two markers in Mül-lerian carcinomas in fluid specimens. In this study, we discovered that the majority of metastatic carcinomas of Müllerian origin were immunoreactive for PAX8 in effusions with high sensitivity (96%). Specifically, in all but two serous carcinomas and in all of the metastatic carcinomas originating from carcinosarcomas, clear cell carcinomas, and endometrioid carcinoma, PAX8 immunoreactivity was seen in at least 25% of the tumor cells. This is concordant with the findings by Bowen et al. which showed a high frequency of PAX8 immunoreactivity in various subtypes of ovarian carcinomas. 16 Furthermore, our results are complementary to those reported by Davidson et al. who applied gene expression profiling to malignant effusions; they reported increased gene expression of PAX8 in serous carcinomas in fluid specimens. 22 Next, we sought to determine whether PAX8 immunopositivity was specific for Müllerian carcinomas by examining the expression of PAX8 in non-Müllerian carcinomatous effusions in parallel. Lung, breast, gastrointestinal, and pancreaticobiliary carcinomas represent common etiologies for malignant effusions. 3 We found that 100% of breast, gastrointestinal, and pancreaticobiliary carcinomas and 97% of lung carcinomas in our study were negative for PAX8. Of note, all 20 of the lung adenocarcinomas, the subtype of lung carcinoma most likely to mimic Müllerian adenocarcinoma, were not immunoreactive for PAX8. These results are consistent with prior reports by Nonaka and colleagues that PAX8 is a highly specific marker for distinguishing Müllerian carcinomas from these non-Müllerian carcinomas. 20, 23 PAX8 immunoreactivity in effusions was seen in only four non-Müllerian carcinomas including metastatic papillary thyroid carcinoma and renal cell carcinoma. This can be reconciled in light of the finding that PAX8 is expressed in thyroid follicular epithelium and renal tubular epithelium as well as thyroid carcinomas and renal cell carcinomas. 23, 24 It should be noted that carcinomas of thyroid and renal origin rarely metastasize to fluids 10 explaining the low number of these malignant effusions in our study population; nonetheless, our results confirm that PAX8 can be useful in confirming the presence of metastatic carcinomas from the thyroid and kidney in effusions. We also found one case each of a large cell neuroendocrine lung carcinoma and an acinic cell carcinoma of the salivary gland to be immunoreactive for PAX8. These also represent malignancies that seldomly metastasize to effusions and because the expression of PAX8 in these malignancies have not been studied in detail, additional studies will be required to determine the frequency of PAX8 positivity in these cancers. Nonetheless, our results overall demonstrate that PAX8 is a highly sensitive and specific marker for metastatic carcinomas of Müllerian origin in fluids.
We sought to ascertain the sensitivity and specificity of PAX2 as a marker for Müllerian carcinomas. In contrast to PAX8, PAX2 was only positive in 24% of the Müller-ian carcinomas in this study. This contrasts with the findings by Tong et al. who showed that over half of serous carcinomas are immunoreactive for PAX2. 18 Nonetheless, our results can be reconciled in light of the more recent finding that the proportion of high-grade serous carcinomas that express PAX2 at the mRNA and protein level is significantly less than that of low grade serous carcinomas. 25 It should be noted that none of the serous carcinomas in our study were low grade. Of note, PAX2 expression has been found in 61-85% of renal cell carcinomas. 26, 27 Although our one case of metastatic renal cell carcinoma was negative for PAX2, it is likely that others may be PAX2 positive.
Finally, the cytomorphologic patterns of malignant mesothelioma in effusions can mimic those of carcinomas, especially those of Müllerian origin. Although the expression of PAX8 in mesothelioma is not well characterized, the majority of mesotheliomas appear to be negative for PAX2. Specifically, one previous study demonstrated that only two of 54 mesothelioma cases were immunoreactive for PAX2. 18 Although additional studies examining the expression of PAX8 and PAX2 in mesotheliomas are needed, a panel of immunostains utilizing other antibodies such as those directed against calretinin, MOC-31, BerEP4, B72.3, and Leu-M1 can be helpful in distinguishing Mül-lerian carcinomas from mesotheliomas in effusions. 6 In conclusion, our study demonstrates that both PAX8 and PAX2 are specific markers for identifying metastatic Müllerian carcinomas in effusions (96% and 100%, respectively). PAX8, however, is a more sensitive marker for Müllerian carcinomas than PAX2 (96% versus 24%). Nonetheless, we demonstrate the diagnostic utility of PAX8 and PAX2 in identifying and distinguishing carcinomatous effusions of Müllerian origin from those of non-Müllerian origin. 
